重症哮喘治疗新药reslizumab  

Reslizumab,a novel drug for treating severe asthma

作　　者：杜朝阳[1,2] 孙路路[1] DU Zhao-yang SUN Lu-lu(Department of Pharmacy, Beijing Shijitan Hospital to Capital Medical University, Beijing 100038, China Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University Health Science Center, Beijing 100191, China)

机构地区：[1]首都医科大学附属北京世纪坛医院药剂科,北京100038 [2]北京大学药学院药事管理与临床药学系,北京100191

出　　处：《中国新药杂志》2017年第3期257-260,共4页Chinese Journal of New Drugs

摘　　要：reslizumab(商品名:Cinqair)是一种人源化的白介素-5(IL-5)重组单克隆抗体,2016年3月23日美国FDA批准其上市用于年龄≥18岁的重症嗜酸性粒细胞哮喘患者的附加维持治疗。该药是一种全新作用机制的抗哮喘药,临床使用效果良好,每4周静脉注射3 mg·kg-1reslizumab可改善肺功能和控制哮喘,主要不良反应为口咽疼痛。本文对reslizumab的作用机制、药效学、药动学、药物相互作用、临床评价和安全性等进行综述。Reslizumab,with a brand name of Cinqair,is a humanised monoclonal interleukin-5（IL-5）antibody. It was approved by the US FDA on 23 th March,2016 for patients aged ≥ 18 years as add-on maintenance treatment for severe asthma with an eosinophilic phenotype. Monthly intravenous 3. 0 mg·kg^-1reslizumab had resulted in improvements in lung function and asthma control. The drug is an anti-asthma drug of new mechanism and has desirable efficacy,which main adverse reaction is oropharyngeal pain. In this article,the mechanism,pharmacodynamics,pharmacokinetics,drug interaction,clinical evaluation,and safety of reslizumab were reviewed.

关 键 词：reslizumab 重症哮喘 白介素-5(IL-5)重组单克隆抗体 

分 类 号：R974.3[医药卫生—药品]